FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)

FDA decision on Ifinatamab Deruxtecan in 2026 If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting pro